Alpha 2.0
Login Register
» Articles » PMID: 31106402

Deferasirox in the Management of Iron-overload in Patients with Myelofibrosis: a Multicentre Study from the Rete Ematologica Lombarda (IRON-M Study)

Overview
Journal Br J Haematol
Specialty Hematology
Date 2019 May 21
PMID 31106402
Citations 5
Authors
Elena M Elli
Alessandra Iurlo
Andrea Aroldi
Marianna Caramella
Simona Malato
Elena Casartelli
Margherita Maffioli
Angelo Gardellini
Maria C Carraro
Mariella DAdda
Nicola Polverelli
Marianna Rossi
Nicola Orofino
Andrea Carrer
Carlo Gambacorti-Passerini
Laura Antolini
Francesco Passamonti
Affiliations
Soon will be listed here.
Citing Articles

ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.

Duminuco A, Chifotides H, Giallongo S, Giallongo C, Tibullo D, Palumbo G Cancers (Basel). 2024; 16(1).

PMID: 38201581 PMC: 10778144. DOI: 10.3390/cancers16010154.

Luspatercept: A New Tool for the Treatment of Anemia Related to β-Thalassemia, Myelodysplastic Syndromes and Primary Myelofibrosis.

Hatzimichael E, Timotheatou D, Koumpis E, Benetatos L, Makis A Diseases. 2022; 10(4).

PMID: 36278584 PMC: 9624301. DOI: 10.3390/diseases10040085.

How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation.

Polverelli N, Farina M, DAdda M, Damiani E, Grazioli L, Leoni A Cells. 2022; 11(3).

PMID: 35159362 PMC: 8834299. DOI: 10.3390/cells11030553.

From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox.

Palumbo G, Galimberti S, Barcellini W, Cilloni D, Di Renzo N, Elli E Front Oncol. 2021; 11:752192.

PMID: 34692534 PMC: 8527180. DOI: 10.3389/fonc.2021.752192.

Standard care and investigational drugs in the treatment of myelofibrosis.

Barraco D, Maffioli M, Passamonti F Drugs Context. 2019; 8:212603.

PMID: 31645880 PMC: 6788389. DOI: 10.7573/dic.212603.